Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American College Of Cardiology Scientific Sessions, In Brief

Executive Summary

Dual renin-angiotensin system inhibition is better: Combining Novartis' newly approved direct renin inhibitor Tekturna (aliskiren) with the firm's angiotensin receptor blocker Diovan (valsartan) yields better antihypertensive efficacy than either monotherapy. In a 1,797-patient placebo-controlled study, a combination of aliskiren 300 mg and valsartan 320 mg produces significantly greater blood pressure control rates (49.3% reaching <140/90 mmHg vs. 37.4% for aliskiren, 33.8% for valsartan and 16.5% for placebo), "provides significant additional BP lowering of up to 4.5/3.2 mmHg over [aliskiren] or [valsartan] alone and retains the excellent tolerability of [aliskiren] and [valsartan] monotherapy," the abstract states. Other aliskiren data presented at ACC include an analysis showing BP reductions persisted up to four weeks after discontinuation and a comparative study showing that more patients on Tekturna reached their BP goal than on the ACE inhibitor ramipril (61.4% vs. 53.1%, respectively). Novartis is positioning Tekturna for use in combination therapy, building on its potentially complementary mechanism of action...

You may also be interested in...

Will Novartis’ Tekturna Be Buoyed By Category Captainship?

The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas

GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King

Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes

FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article

The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts